Interest of CA 125 level in management of ovarian cancer;Intérêt du dosage du CA 125 dans la prise en charge du cancer de l'ovaire

Gynecologie Obstetrique et Fertilite

Volumn 39, Issue 5, 2011, Pages 296-301

  Coussy, F ^a   Chereau E ^a   Darai E ^a   Dhombres, F ^a   Lotz, J P ^a   Rouzier, R ^a   Selle, F ^a  

^a HÔPITAL TENON   (France)

Author keywords

Adjuvant chemotherapy; CA 125; Cytoreduction; Diagnosis; Neo adjuvant chemotherapy; Ovarian cancer; Recurrence; Screening

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DISEASE MARKER; GYNECOLOGIC SURGERY; HUMAN; OVARY CANCER; PERSONALIZED MEDICINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REVIEW;

EID: 79955929781     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2010.10.018     Document Type: Article

References (47)

1. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4(1):1-12. (Pubitemid 19069900)
2. Menon U, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10(4):327-40.
3. Van Calster B, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 2007;99(22):1706-14. (Pubitemid 351767215)
4. Cooper BC, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002;100(1):59-64. (Pubitemid 34722843)
5. Timmerman D, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol 2005;23(34):8794-801. (Pubitemid 46211525)
6. Timmerman D, et al. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol 2007;25(27):4194-200. (Pubitemid 47548558)
7. Vorgias G, et al. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol 2009;112(1):11-5.
8. Riedinger JM, et al. Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV. Bull Cancer 1996;83(8):654-63. (Pubitemid 26273034)
9. Kang S, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol 2010;101(1):13-7.
10. Chi DS, et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77(2):227-31. (Pubitemid 30317140)
11. Chi DS, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 2009;112(1):6-10.
12. Fagotti A, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006;13(8):1156-61. (Pubitemid 44337976)
13. Brun JL, et al. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol 2008;110(3):354-9.
14. Eisenkop SM, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003;90(2):390-6. (Pubitemid 36952033)
15. Saygili U, et al. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 2002;86(1):57-61.
16. Memarzadeh S, et al. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2003;13(2):120-4. (Pubitemid 37055464)
17. Eltabbakh GH, et al. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 2004;95(2):377-83. (Pubitemid 39445875)
18. Gemer O, Segal S, Kopmar A. Preoperative CA-125 level as a predictor of nonoptimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 2001;80(6):583-5. (Pubitemid 32521301)
19. Gemer O, et al. A multicenter study of CA 125 level as a predictor of nonoptimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 2005;31(9):1006-10. (Pubitemid 41671115)
20. Barlow TS, et al. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 2006;16(2):496-500.
21. Arits AH, et al. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 2008;18(4):621-8. (Pubitemid 352020153)
22. Gadducci A, et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995;58(1):42-7.
23. Gasowska-Bodnar A, et al. CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction. Ginekol Pol 2008;79(2):108-14.
24. Riedinger JM. Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study. Bull Cancer 2007;94(3):287-95.
25. Tate S, et al. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 2005;96(1):143-9. (Pubitemid 39612429)
26. Le T, et al. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer. J Obstet Gynaecol Can 2008;30(8):665-70.
27. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006;103(3):1070-6. (Pubitemid 44821335)
28. van der Burg ME, et al. Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988;30(3):307-12.
29. Hawkins RE, et al. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989;96(12):1395-9. (Pubitemid 20020045)
30. Yedema CA, et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993;67(6):1361-7. (Pubitemid 23172879)
31. Gadducci A, et al. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 2004;93(1):131-6. (Pubitemid 38429561)
32. Sevelda P, Schemper M, Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989;161(5):1213-6. (Pubitemid 20007685)
33. Redman CW, et al. Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990;26(5):593-6. (Pubitemid 20259337)
34. Yedema CA, et al. CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 1993;29A(7):966-71. (Pubitemid 23126693)
35. Ron IG, et al. Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand 1994;73(8):658-62.
36. Markman M, et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006;24(9):1454-8. (Pubitemid 46622013)
37. Paramasivam S, et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol 2005;23(25):5938-42.
38. Nagele F, et al. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995;86(2):259-64.
39. Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005;16(1):47-50.
40. van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990;1(4):301-2. (Pubitemid 20377102)
41. Rustin GJ, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125, a North Thames Ovary Group Study. Ann Oncol 1996;7(4):361-4. (Pubitemid 26246787)
42. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92(3):205-16. (Pubitemid 30099779)
43. Liu PY, et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 2007;25(24):3615-20.
44. Markman M, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21(13):2460-5. (Pubitemid 46606325)
45. Prat A, et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol 2009;20(2):294-7.
46. Han LY, et al. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. EUR J Cancer 2010;46(8):1359-64.
47. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 2007;8(9):813-21. (Pubitemid 47308670)